RHuEPo reduces ischemia-reperfusion injury and improves survival after transplantation of fatty livers in rats

Transplantation

Volumn 89, Issue 2, 2010, Pages 161-168

  Schmeding, Maximilian ^a   Rademacher, Sebastian ^a   Boas Knoop, Sabine ^a   Roecken, Christoph ^a   Lendeckel, Uwe ^a   Neuhaus, Peter ^a   Neumann, Ulf P ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Epo; Erythropoietin; Fatty liver; Ischemia reperfusion injury; Liver transplantation; Marginal organs

Indexed keywords

ALANINE AMINOTRANSFERASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIVER ENZYME; MESSENGER RNA; RECOMBINANT ERYTHROPOIETIN; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; COLD ISCHEMIA; CONTROLLED STUDY; FATTY LIVER; GENE EXPRESSION; HISTOPATHOLOGY; HYPOXIC CELL; IMMUNOHISTOCHEMISTRY; LIVER GRAFT; LIVER ISCHEMIA; LIVER REGENERATION; LIVER TRANSPLANTATION; MALE; NICK END LABELING; NONHUMAN; OVERALL SURVIVAL; PORTAL VEIN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE;

ANIMALS; ERYTHROPOIETIN; FATTY LIVER; GRAFT REJECTION; GRAFT SURVIVAL; HEPATOCYTE GROWTH FACTOR; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIVER TRANSPLANTATION; MALE; RATS; RATS, INBRED LEW; RECOMBINANT PROTEINS; RNA, MESSENGER; SURVIVAL RATE; SURVIVORS; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 76649102745     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181c425fd     Document Type: Article

References (44)

1. Amin MG, Wolf MP, TenBrook JA Jr, et al. Expanded criteria donor grafts for deceased donor liver transplantation under the MELD system: A decision analysis. Liver Transpl 2004; 10: 1468.
2. Merion RM, Schaubel DE, Dykstra DM, et al. The survival benefit of liver transplantation. Am J Transplant 2005; 5: 307.
3. Schaubel DE, Sima CS, Goodrich NP, et al. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008; 8: 419.
4. Arnault I, Bao YM, Sebagh M, et al. Beneficial effectofpentoxifylline on microvesicular steatotic livers submitted to a prolonged cold ischemia. Transplantation 2003; 76: 77.
5. Chavin KD, Fiorini RN, Shafizadeh S, et al. Fatty acid synthase blockade protects steatotic livers from warm ischemia reperfusion injury and transplantation. Am J Transplant 2004; 4: 1440.
6. Lehmann TG, Wheeler MD, Froh M, et al. Effects of three superoxide dismutase genes delivered with an adenovirus on graft function after transplantation of fatty livers in the rat. Transplantation 2003; 76: 28.
7. Selzner N, Selzner M, Jochum W, et al. Mouse livers with macrosteato-sis are more susceptible to normothermic ischemic injury than those with microsteatosis. J Hepatol 2006; 44: 694.
8. Selzner N, Selzner M, Jochum W, et al. Ischemic preconditioning protects the steatotic mouse liver against reperfusion injury: An ATP dependent mechanism. J Hepatol 2003; 39: 55.
9. Soejima Y, Shimada M, Suehiro T, et al. Use of steatotic graft in living-donor liver transplantation. Transplantation 2003; 76: 344.
10. Kaygisiz Z, Erkasap N, Yazihan N, et al. Erythropoietin changes contractility, cAMP, and nitrite levels of isolated rat hearts. J Physiol Sci 2006; 56: 247.
11. Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of eryth-ropoietin in the infarcted heart. J Clin Invest 2003; 112: 999.
12. Villa P, van Beek J, Larsen AK, et al. Reduced functional deficits, neu-roinflammation, and secondary tissue damage after treatmentof stroke by nonerythropoietic erythropoietin derivatives. J Cereb Blood Flow Metab 2007; 27: 552.
13. Abdelrahman M, Sharples EJ, McDonald MC, et al. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 2004; 22: 63.
14. Johnson DW, Forman C, Vesey DA. Novel renoprotective actions of erythropoietin: New uses for an old hormone. Nephrology (Carlton) 2006; 11: 306.
15. Sepodes B, Maio R, Pinto R, et al. Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat. Transpl Int 2006; 19: 919.
16. Schmeding M, Neumann UP, Boas-Knoop S, et al. Erythropoietin reduces ischemia-reperfusion injury in the rat liver. Eur Surg Res 2007; 39: 189.
17. Hochhauser E, Pappo O, Ribakovsky E, et al. Recombinant human erythropoietin attenuates hepatic injury induced by ischemia/reperfu-sion in an isolated mouse liver model. Apoptosis 2008; 13: 77.
18. Schmeding M, Hunold G, Ariyakhagorn V, et al. Erythropoietin reduces ischemia-reperfusion injury after liver transplantation in rats. Transpl Int 2009; 22: 738.
19. Schmeding M, Boas-Knoop S, Lippert S, et al. Erythropoietin promotes hepatic regeneration after extended liver resection in rats. J Gastroen-terol Hepatol 2008; 23: 1125.
20. Mingoli A, Sapienza P, Puggioni A, et al. A possible side-effect of human erythropoietin therapy: Thrombosis of peripheral arterial reconstruction. Eur J Vasc Endovasc Surg 1999; 18: 273.
21. Shinaberger JH, Miller JH, Gardner PW. Erythropoietin alert: Risks of high hematocrit hemodialysis. ASAIO Trans 1988; 34: 179.
22. Nishiya D, Omura T, Shimada K, et al. Effects of erythropoietin on cardiac remodeling after myocardial infarction. J Pharmacol Sci 2006; 101: 31.
23. Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003; 100: 4802.
24. Li XL, Man K, Ng KT, et al. The influence of phosphatidylinositol 3-kinase/Akt pathway on the ischemic injury during rat liver graft preservation. Am J Transplant 2005; 5: 1264.
25. Uehara T, Bennett B, Sakata ST, et al. JNK mediates hepatic ischemia reperfusion injury. J Hepatol 2005; 42: 850.
26. Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: A tale of two deaths? Hepatology 2006; 43(2 suppl 1): S31.
27. Chang YS, Mu D, Wendland M, et al. Erythropoietin improves functional and histological outcome in neonatal stroke. Pediatr Res 2005; 58: 106.
28. Gunnarson E, Song Y, Kowalewski JM, et al. Erythropoietin modulation of astrocyte water permeability as a component of neuroprotec-tion. Proc Natl Acad Sci USA 2009; 106: 1602.
29. Iwai M, Cao G, Yin W, et al. Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia/ischemia in rats. Stroke 2007; 38: 2795.
30. Camargo CA Jr, Madden JF, Gao W, et al. Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology 1997; 26: 1513.
31. Wustefeld T, Rakemann T, Kubicka S, et al. Hyperstimulation with interleukin 6 inhibits cell cycle progression after hepatectomy in mice. Hepatology 2000; 32: 514.
32. Cariou A, Claessens YE, Pene F, et al. Early high-dose erythropoietin therapy and hypothermia after out-of-hospital cardiac arrest: A matched control study. Resuscitation 2008; 76: 397.
33. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit het-eroreceptor. Proc Natl Acad Sci USA 2004; 101: 14907.
34. Ingley E, Tilbrook PA, Klinken SP. New insights into the regulation of erythroid cells. IUBMB Life 2004; 56: 177.
35. Rafiee P, Shi Y, Su J, et al. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res Cardiol 2005; 100: 187.
36. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoi-etin. JAMA 2005; 293: 90.
37. Ruscher K, Freyer D, Karsch M, et al. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: Evidence from an in vitro model. J Neurosci 2002; 22: 10291.
38. Kiemer AK, Vollmar AM, Bilzer M, et al. Atrial natriuretic peptide reduces expression of TNF-alpha mRNA during reperfusion of the rat liver upon decreased activation of NF-kappaB and AP-1. J Hepatol 2000; 33: 236.
39. Schauer RJ, Gerbes AL, Vonier D, et al. Glutathione protects the rat liver against reperfusion injury after prolonged warm ischemia. Ann Surg 2004; 239: 220.
40. Defamie V, Laurens M, Patrono D, et al. Matrix metalloproteinase inhibition protects rat livers from prolonged cold ischemia-warm reperfusion injury. Hepatology 2008; 47: 177.
41. Fondevila C, Shen XD, Tsuchiyashi S, et al. Biliverdin therapy protects rat livers from ischemia and reperfusion injury. Hepatology 2004; 40: 1333.
42. Hamada T, Fondevila C, Busuttil RW, Coito AJ. Metalloproteinase-9 deficiency protects against hepatic ischemia/reperfusion injury. Hepa-tology 2008; 47: 186.
43. Mueller TH, Kienle K, Beham A, et al. Caspase 3 inhibition improves survival and reduces early graft injury after ischemia and reperfusion in rat liver transplantation. Transplantation 2004; 78: 1267.
44. Nakajima H, Mizuta N, Fujiwara I, et al. Blockade of the Fas/Fas ligand interaction suppresses hepatocyte apoptosis in ischemia-reperfusion rat liver. Apoptosis 2008; 13: 1013.